redit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for Ix Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Copaxone for MYL (worth $1 to his DCF). For MNTA (partnered w/ Sandoz/NVS), they